Nanobiotix S.A. (NANO.PA)
- Previous Close
3.1200 - Open
3.1100 - Bid --
- Ask --
- Day's Range
2.9800 - 3.1150 - 52 Week Range
2.6200 - 6.9650 - Volume
106,219 - Avg. Volume
136,041 - Market Cap (intraday)
142.925M - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4400 - Earnings Date May 20, 2025 - May 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.35
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
www.nanobiotix.comRecent News: NANO.PA
View More
Performance Overview: NANO.PA
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NANO.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NANO.PA
View MoreValuation Measures
Market Cap
147.90M
Enterprise Value
149.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.50
Price/Book (mrq)
--
Enterprise Value/Revenue
3.39
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.89%
Return on Equity (ttm)
--
Revenue (ttm)
-7.19M
Net Income Avi to Common (ttm)
-68.13M
Diluted EPS (ttm)
-1.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
49.74M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-33.16M